2. Valderas J.M. et al. Research on patients with multiple health conditions: different constructs, different views, one voice. J Comorb. 2011 Dec 27; 1: 1–3. PMID: 29090129.

3. de Groot V. et al. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003 Mar; 56(3): 221–29. PMID: 12725876.

4. Fabbri L.M. et al. Complex chronic comorbidities of COPD. Eur Respir J. 2008 Jan; 31(1): 204–12. doi: 10.1183/09031936.00114307.

5. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017; http://goldcopd.org

6. Кароли Н.А. с соавт. Коморбидность при хронической обструктивной болезни легких. Терапевтический архив. 2008; 80(3): 20–24.

7. Кароли Н.А., Ребров А.П. Артериальная гипертензия у больных хронической обструктивной болезнью лег- ких. Фарматека. 2010; 18–19: 62–69.

8. Кароли Н.А., Ребров А.П. Артериальная гипертензия у пациентов с бронхиальной астмой и хронической обструктивной болезнью легких. Клиницист. 2011; 2: 20–30.

9. Кароли Н.А. с соавт. Коморбидность при хронической обструктивной болезни легких. Журнал сердечная недостаточность. 2008; 9(1): 41–43.

10. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019; https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7- FINAL-14Nov2018-WMS.pdf.

11. Woodruff P.G. et al. SPIROMICS Research Group. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. N Engl J Med. 2016 May 12; 374(19): 1811–21. doi: 10.1056/NEJMoa1505971.

12. Jetmalani K. et al. Peripheral airway dysfunction and relationship with symptoms in smokers with preserved spirometry. Respirology. 2018 May; 23(5): 512–18. doi: 10.1111/resp.13215.

13. Mirza S. et al. Chronic obstructive pulmonary disease phenotypes: implications for care. Mayo Clin Proc. 2017 Jul; 92(7): 1104–12. doi: 10.1016/j.mayocp.2017.03.020.

14. Han M.K. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010 Sep 1; 182(5): 598–604. doi: 10.1164/rccm.200912-1843CC.

15. Авдеев C.Н. Фенотипы хронической обструктивной болезни легких: особенности терапии. Болезни органов дыхания. Приложение к журналу Consilium Medicum. 2010; 1: 23–28.

16. Burgel P.R.et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J. 2010 Sep; 36(3): 531–39. doi: 10.1183/09031936.

17. Miravitlles M. et al. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012 Mar; 48(3): 86–98. doi: 10.1016/j.arbres.2011.10.007.

18. Burgel P.R. et al. Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities. Biomed Res Int. 2014; 2014: 420134. doi: 10.1155/2014/420134.

19. Camiciottoli G. et al. Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016 Sep 14; 11: 2229–36. doi: 10.2147/COPD. S111724.

20. Enriquez J.R. et al. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute Dynamic Registry. Chest. 2011 Sep; 140(3): 604–10. doi: 10.1378/chest.10-2644.

21. Man S.F. et al. Is atherosclerotic heart disease in COPD a distinct phenotype? Chest. 2011 Sep; 140(3): 569–71. doi: 10.1378/chest.11-0928.

22. Schols A.M. et al. Nutritional assessment and therapy in COPD: a European Respiratory Society statement. Eur Respir J. 2014 Dec; 44(6): 1504–20. doi: 10.1183/09031936.00070914.

23. Young R.P. et al. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev. 2009 Dec; 18(114): 222–32. doi: 10.1183/09059180.00005309.

24. Young R.P. et al. Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities. Expert Rev Respir Med. 2013 Oct; 7(5): 533–44. doi: 10.1586/17476348.2013.838018.

25. Abboud R.T. et al. Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema. Int J Tuberc Lung Dis. 2008 Apr; 12(4): 361–67. PMID: 18371259.

26. Barnes P.J. et al. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003 Oct; 22(4): 672–88. PMID: 14582923.

27. Bagdonas E. et al. Novel aspects of pathogenesis and regeneration mechanisms in COPD. Int J Chron Obstruct Pulmon Dis. 2015 Jun 2; 10: 995–1013. doi: 10.2147/COPD.S82518.

28. Tetley T.D. Macrophages and the pathogenesis of COPD. Chest. 2002 May; 121(5 Suppl):156S–159S. PMID: 12010845.

29. Decramer M. et al. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013 Mar; 1(1): 73–83. doi: 10.1016/S2213-2600(12)70060-7.

30. Ли В.В., Задионченко В.С., Адашева Т.В. с соавт. Хроническая обструктивная болезнь легких и артериаль- ная гипертония – метафизика и диалектика. CardioСоматика. 2013; 4(1): 5–10.

31. Papi A. et al. Phenomenology of COPD: interpreting phenotypes with the ECLIPSE study. Monaldi Arch ChestDis. 2016 Oct 14; 83(1–2): 721. doi: 10.4081/monaldi.2016.721.

32. Айсанов З.Р. с соавт. Национальные клинические рекомендации по диагностике и лечению хроническойобструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017; 27(1): 13–20. https://doi.org/10.18093/0869-0189-2017-27-1-13-20.

33. Chow C.K. et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013 Sep 4; 310(9): 959–68. doi: 10.1001/jama.2013.184182.

34. Stokes J. 3rd et al. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study--30 years of follow-up. Hypertension. 1989 May; 13(5 Suppl): I13–8. PMID: 2535213.

35. Williams B. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1; 39(33): 3021–104. doi: 10.1093/eurheartj/ehy339.

36. Mancia G. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul; 31(7): 1281–357. doi: 10.1097/01.hjh.0000431740.32696.cc.

37. Чазова И.Е. с соавт. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 54(10): 4–12. PMID: 25675714.

38. Оганов Р.Г. с соавт. Эпидемиология артериальной гипертонии в России. Результаты федерального мони- торинга 2003–2010 гг. Кардиоваскулярная терапия и профилактика. 2011; 10(1): 9–13.

39. Кобалава Ж.Д. с соавт. Меморандум Российского кардиологического общества по рекомендациям Европейского общества кардиологов/Европейского общества по артериальной гипертензии по лечению артериальной гипертензии 2018 г. Российский кардиологический журнал. 2018; 23(12): 131–42. http://dx.doi. org/10.15829/1560-4071-2018-12-131-142.

40. Чучалин А.Г. с соавт. Российское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 3: 15–54. https:// doi.org/10.18093/0869-0189-2014-0-3-15-54.

41. Lozano R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2095–128. doi: 10.1016/S0140-6736(12)61728-0.

42. Обрезан А.Г. с соавт. Хроническая обструктивная болезнь легких и коморбидные кардиоваскулярные заболевания у лиц пожилого и старческого возраста: проблемы диагностики лечения (обзор литературы). Вестник СПбГУ. 2010; 11(2): 51–66.

43. Mannino D.M. et al. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease. Eur Respir J. 2008 Oct; 32(4): 962–69. doi: 10.1183/09031936.00012408.

44. Pływaczewski R. et al. Causes of death in COPD patients in primary care setting – a 6-year follow-up. Pneumonol Alergol Pol. 2015; 83(3): 193–202. doi: 10.5603/PiAP.2015.0031.

45. Кароли Н.А., Ребров А.П. Хронический обструктивный бронхит и ишемическая болезнь сердца. Клиническаямедицина. 2006; 3: 72–77.

46. Anthonisen N.R. et al.; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002 Aug 1; 166(3): 333–39. doi: 10.1164/rccm.2110093.

47. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2014 г.). Пер. с англ. под ред. А.С. Белевского. Российское респираторное общество. 2014; https://goldcopd.org/wpcontent/uploads/2016/04/GOLD_Report_Russian_2014.pdf.

48. Кароли Н.А., Ребров А.П. Коморбидность у больных хронической обструктивной болезнью легких: место кардиоваскулярной патологии. Рациональная фармакотерапия в кардиологии. 2009; 5(4): 9–16.

49. Figueira Goncalves J.M. et al. Cardiovascular comorbidity in patients with chronic obstructive pulmonary disease in the Canary Islands (CCECAN study). Clin Investig Arterioscler. 2017 Jul – Aug; 29(4): 149–56. doi: 10.1016/j.arteri.2017.01.003.

50. Adamson P.D. et al. Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. J Am Coll Cardiol. 2018 Sep 4; 72(10): 1126–37. doi: 10.1016/j.jacc.2018.06.051.

51. Finkelstein J. et al. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009; 4: 337–49. PMID: 19802349.

52. Chen W. et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015 Aug; 3(8): 631–39. doi: 10.1016/S2213- 2600(15)00241-6.

53. Onishi K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J Cardiol. 2017 Aug; 70(2): 128–34. doi: 10.1016/j.jjcc.2017.03.001.

54. Lahousse L. et al. Chronic obstructive pulmonary disease and sudden cardiac death: the Rotterdam study. Eur Heart J. 2015 Jul 14; 36(27): 1754–61. doi: 10.1093/eurheartj/ehv121.

55. Shibata Y. et al. A lower level of forced expiratory volume in 1 second is a risk factor for all-cause and cardiovascular mortality in a Japanese population: the Takahata study. PLoS One. 2013 Dec 13; 8(12): e83725. doi: 10.1371/journal.pone.0083725.

56. Macnee W. et al. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008 Dec 1; 5(8): 824–33. doi: 10.1513/pats.200807-071TH.

57. Mazza A. et al. Chronic obstructive pulmonary disease and cardiovascular mortality in elderly subjects from general population. Blood Press. 2010 Apr; 19(2): 67–74. doi: 10.3109/08037050903464642.

58. Chronic Obstructive Pulmonary Disease. Guidelines for Clinical Care Ambulatory. University of Michigan health system (UMHS) COPD Guideline, November 2017; http://www.med.umich.edu/1info/FHP/practiceguides/copd/ copd.pdf.

59. Sin D.D. et al. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol. 2005 Jan; 83(1): 8–13. doi: 10.1139/y04-116.

60. Sin D.D. et al. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005 Jun; 127(6): 1952–59. doi: 10.1378/chest.127.6.1952.

61. Iversen K.K. et al. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail. 2010 Jul; 12(7): 685–91. doi: 10.1093/eurjhf/hfq050.

62. Engstrom G. et al. Respiratory decline in smokers and ex-smokers – an independent risk factor for cardiovascular disease and death. J Cardiovasc Risk. 2000 Aug; 7(4): 267–72. PMID: 11006897.

63. Truelsen T. et al. Lung function and risk of fatal and non-fatal stroke. The Copenhagen City Heart Study. Int J Epidemiol. 2001 Feb; 30(1): 145–51. PMID: 11171876.

64. Sorlie P.D. et al. Mortality associated with respiratory function and symptoms in advanced age. The Framingham Study. Am Rev Respir Dis. 1989 Aug; 140(2): 379–84. doi:10.1164/ajrccm/140.2.379.

65. Задионченко В.С. с соавт. Артериальная гипертония при хронической обструктивной болезни легких.«Анахарсис». 2005: 172. ISBN 5-901352-41-6.

66. Мухарлямов Н.М. с соавт. Системная артериальная гипертензия у больных хроническими неспецифически- ми заболеваниями легких. Кардиология.1974; 12(34): 55–61.

67. Жданов В.Ф. Клинико-статистическая характеристика больных неспецифическими заболеваниями легких с системной артериальной гипертензией. «Актуальные проблемы пульмонологии», сб. науч. тр., Л. 1991; 89–93.

68. Кубышкин В.Ф. с соавт. Особенности течения хронических обструктивных заболеваний легких в сочетании с системной артериальной гипертензией. Терапевтический архив. 1985; 2(57): 114–16.

69. Бобров В.А. с соавт. Системная артериальная гипертензия при хроническом обструктивном бронхите: современные взгляды и новые понимания. Клиническая медицина. 1995; 3: 24.

70. Серебрякова В.И. Клинико-патологические особенности нейроэндокринной регуляции при сочетании артериальной гипертензии с лабильной и стабильной обструкции бронхов в возрастном и половом аспекте, коррекция выявленных нарушений. Авт. дис. … д-ра мед. наук. СПб., 1998.

71. Ольбинская Л.И. с соавт. Суточный профиль артериального давления при хронических обструктивных заболеваниях легких и при их сочетании с артериальной гипертензией. Российский кардиологический журнал. 2000; 2: 20–25.

72. Палеев Н.Р. с соавт. Существует ли «пульмогенная гипертензия»? Кардиология. 2002; 6: 51–53.

73. Hill K. et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ. 2010 Apr 20; 182(7): 673–78. doi: 10.1503/cmaj.091784.

74. Echave J.M. et al. Comorbidity in COPD in Spain. Am J Respir Crit Care Med. 2009; 179: А1462.

75. Sidney S. et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005 Oct; 128(4): 2068–75. doi: 10.1378/chest.128.4.2068.

76. Holguin F. et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005 Oct; 128(4): 2005–11. doi: 10.1378/chest.128.4.2005.

77. Baty F. et al. Comorbidities and burden of COPD: a population based case-control study. PLoS One. 2013 May 17; 8(5): e63285. doi: 10.1371/journal.pone.0063285.

78. Jo Y.S. et al. The relationship between chronic obstructive pulmonary disease and comorbidities: a cross- sectional study using data from KNHANES 2010–2012. Respir Med. 2015 Jan; 109(1): 96–104. doi: 10.1016/j. rmed.2014.10.015.

79. Kim S.H. et al. Chronic obstructive pulmonary disease is independently associated with hypertension in men. A survey design analysis using nationwide survey data. Medicine (Baltimore). 2017 May; 96(19): e6826. doi: 10.1097/MD.0000000000006826.

80. Onishi K. et al. Prevalence of airflow limitation in outpatients with cardiovascular diseases in Japan. Int J Chron Obstruct Pulmon Dis. 2014 May 29; 9: 563–68. doi: 10.2147/COPD.S59962.

81. Rabahi M.F. et al. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis. 2015 Jul 31; 10: 1525–29. doi: 10.2147/COPD.S85588.

82. Briggs A. et al. Development and validation of a prognostic index for health outcome in chronic obstructive pulmonary disease. Arch Intern Med. 2008 Jan 14; 168(1): 71–79. doi: 10.1001/archinternmed.2007.37.

83. Mahishale V. et al. Prevalence and impact of diabetes, hypertension, and cardiovascular diseases in chronic obstructive pulmonary diseases: a hospital-based cross-section study. J Transl Int Med. 2015 Oct-Dec; 3(4): 155–60. doi: 10.1515/jtim-2015-0019.

84. Чазова И.Е. с соавт. Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктивной болезнью легких (Рекомендации Российского медицинского общества по артериальной гипертонии и Российского респираторного общества). Системные гипертензии. 2013; 10 (1): 5–34.

85. Lundback B. et al. Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2003 Feb; 97(2): 115–22. PMID: 12587960.

86. Ezzati M. et al. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003 Sep 13; 362(9387): 847–52. doi: 10.1016/S0140-6736(03)14338-3.

87. Wilson D. et al. Difficulties identifying and targeting COPD and population-attributable risk of smoking for COPD: a population study. Chest. 2005 Oct; 128(4): 2035–42. doi: 10.1378/chest.128.4.2035.

88. Yin P. et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet. 2007 Sep 1; 370(9589): 751–57. doi: 10.1016/S0140-6736(07)61378-6.

89. Hu G. et al. Risk of COPD from exposure to biomass smoke: a metaanalysis. Chest. 2010 Jul; 138(1): 20–31. doi: 10.1378/chest.08-2114.

90. Prescott E. et al. Smoking and risk of myocardial infarction in women and men: longitudinal population study.BMJ. 1998 Apr 4; 316(7137): 1043–47. PMID: 9552903.

91. Yusuf S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11–17; 364(9438): 937–52. doi: 10.1016/S0140- 6736(04)17018-9.

92. Fukuchi Y. et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology. 2004 Nov; 9(4): 458–65. doi: 10.1111/j.1440-1843.2004.00637.x.

93. Centers for Disease Control and Prevention. Prevalence of coronary heart disease: United States, 2006–2010. MMWR Morb Mortal Wkly Rep. 2011 Oct 14; 60(40): 1377–81. PMID: 21993341.

94. Landis S.H. et al. Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012-2013. Int J Chron Obstruct Pulmon Dis. 2014 Jun 6; 9: 597–611. doi: 10.2147/COPD. S61854.

95. Han M.K. et al. Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med. 2007 Dec 15; 176(12): 1179–84. doi: 10.1164/rccm.200704-553CC.

96. Kirkpatrick D.P. et al. Racial and sex differences in chronic obstructive pulmonary disease susceptibility, diagnosis, and treatment. Curr Opin Pulm Med. 2009 Mar; 15(2): 100–04. doi: 10.1097/MCP.0b013e3283232825.

97. Ben-Zaken Cohen S. et al. The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism. Am J Respir Crit Care Med. 2007 Jul 15; 176(2): 113–20. doi: 10.1164/rccm.200611-1655PP.

98. Baron J.A. et al. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol. 1990 Feb; 162(2): 502–14. PMID: 2178432.

99. Romero R. et al. Esopoh Study Investigators. Undiagnosed obesity in hypertension: clinical and therapeutic implications. Blood Press. 2007; 16(6): 347–53. doi: 10.1080/08037050701715117.

100. Neter J.E. et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003 Nov; 42(5): 878–84. doi: 10.1161/01.HYP.0000094221.86888.AE.

101. Eisner M.D. et al. Body composition and functional limitation in COPD. Respir Res. 2007 Jan 29; 8: 7. doi: 10.1186/1465-9921-8-7.

102. Vozoris N.T. et al. Prevalence, risk factors, activity limitation and health care utilization of an obese population based sample with chronic obstructive pulmonary disease. Can Respir J. 2012 May-Jun; 19(3): e18–24. doi: 10.1155/2012/732618.

103. Lam K.B. et al. Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J. 2010 Feb; 35(2): 317–23. doi: 10.1183/09031936.00024709.

104. Sava F. et al. The Impact of Obesity and Metabolic Syndrome in COPD. Bronchitis. 2011; http://www.intechopen. com/books/bronchitis/the-impact-of-obesity-and-metabolic-syndrome-in-copd. doi: 10.5772/21011.

105. Eagan T.M. et al. Body composition and plasma levels of inflammatory biomarkers in COPD. Eur Respir J. 2010 Nov; 36(5): 1027–33. doi: 10.1183/09031936.00194209.

106. Leone N. et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009 Mar 15; 179(6): 509–16. doi: 10.1164/rccm.200807-1195OC.

107. Ora J. et al. Combined effects of obesity and COPD on dyspnea and exercise tolerance. Am J Respir Crit Care Med. 2009 Nov 15; 180(10): 964–71. doi: 10.1164/rccm.200904-0503OC.

108. Tkacova R. Systemic Inflammation in chronic obstructive pulmonary disease: May adipose tissue play a role? Review of the literature and future perspectives. Mediators Inflamm. 2010; 2010: 585989. doi: 10.1155/2010/585989.

109. Самулеева Ю.В. с соавт. Ожирение и метаболические нарушения у больных хронической обструктивной болезнью легких: возможности фенотипирования. Пульмонология. 2014; 5: 32–38. doi:10.18093/0869-0189- 2014-0-5-32-38.

110. Khan A. et al. Resistant hypertension and obstructive sleep apnea. Int J Hypertens. 2013; 2013: 193010. doi: 10.1155/2013/193010.

111. Peppard P.E. et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000 May 11; 342(19): 1378–84. doi: 10.1056/NEJM200005113421901.

112. Narkiewicz K. et al. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation. 1999 Dec 7; 100(23): 2332–35. PMID: 10587337.

113. Nieto F.J. et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community- based study. Sleep Heart Health Study. JAMA. 2000 Apr 12; 283(14): 1829–36. PMID: 10770144.

114. Малявин А.Г. с соавт. Диагностика и ведение пациентов с резистентной артериальной гипертензией и обструктивным апноэ сна (Клинические рекомендации). Терапия. 2018; 1(19): 4–42.

115. Young T. et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med. 1997 Aug 11–25; 157(15): 1746–52. PMID: 9250236.

116. Haas D.C. et al. Age-dependent associations between sleep-disordered breathing and hypertension: importance of discriminating between systolic/diastolic hypertension and isolated systolic hypertension in the Sleep Heart Health Study. Circulation. 2005 Feb 8; 111(5): 614–21. doi: 10.1161/01.CIR.0000154540.62381.CF.

117. Walia H.K. et al. Association of severe obstructive sleep apnea and elevated blood pressure despite antihypertensive medication use. J Clin Sleep Med. 2014 Aug 15; 10(8): 835–43. doi: 10.5664/jcsm.3946.

118. Dudenbostel T. et al. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens. 2012 May; 26(5): 281–87. doi: 10.1038/jhh.2011.47.

119. Grote L. et al. Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension. JHypertens. 2000 Jun; 18(6): 679–85. PMID: 10872551.

120. Lavie P. et al. Sleep apnea syndrome: a possible contributing factor to resistant. Sleep. 2001 Sep 15; 24(6):721–25. PMID: 11560187.

121. Calhoun D.A. et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008 Jun; 51(6): 1403–19. doi: 10.1161/HYPERTENSIONAHA.108.189141.

122. Carey R.M. et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 Nov; 72(5): e53–e90. doi: 10.1161/HYP.0000000000000084.

123. Pronzato C. Chronic obstructive pulmonary disease and obstructive sleep apnea. Association, consequences and treatment. Monaldi Arch Chest Dis. 2010 Dec; 73(4): 155–61. doi: 10.4081/monaldi.2010.285.

124. McNicholas W.T. COPD-OSA Overlap Syndrome: Evolving Evidence Regarding Epidemiology, Clinical Consequences, and Management. Chest. 2017 Dec; 152(6): 1318–26. doi: 10.1016/j.chest.2017.04.160.

125. Taranto-Montemurro L. et al. Cardiac sympathetic hyperactivity in patients with chronic obstructive pulmonary disease and obstructive sleep apnea. COPD. 2016 Dec; 13(6): 706–11. doi: 10.1080/15412555.2016.1199668.

126. McNicholas W.T. Comorbid obstructive sleep apnoea and chronic obstructive pulmonary disease and the risk of cardiovascular disease. J Thorac Dis. 2018 Dec; 10(Suppl 34): S4253–S4261. doi: 10.21037/jtd.2018.10.117.

127. Kendzerska T. et al. Cardiovascular outcomes and all-cause mortality in patients with obstructive sleep apnea and chronic obstructive pulmonary disease (overlap syndrome). Ann Am Thorac Soc. 2019 Jan; 16(1): 71–81. doi: 10.1513/AnnalsATS.201802-136OC.

128. Stewart A.G. et al. Cardiovascular autonomic nerve function in patients with hypoxaemic chronic obstructive pulmonary disease. Eur Respir J. 1991 Nov; 4(10): 1207–14. PMID: 1804668.

129. Costes F. et al. Influence of exercise training on cardiac baroreflex sensitivity in patients with COPD. Eur Respir J. 2004 Mar; 23(3): 396–401. PMID: 15065828.

130. Patakas D. et al. Reduced baroreceptor sensitivity in patients with chronic obstructive pulmonary disease. Thorax. 1982 Apr; 37(4): 292–95. PMID: 7112459.

131. Heindl S. et al. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001 Aug 15; 164(4): 597–601. doi: 10.1164/ajrccm.164.4.2007085.

132. Bartels M.N. et al. Oxygen supplementation and cardiac-autonomic modulation in COPD. Chest. 2000 Sep; 118(3): 691–96. PMID: 10988190.

133. Curtis B.M. et al. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc. 2002 Jan; 77(1): 45–54. doi: 10.4065/77.1.45.

134. Cook S. et al. High heart rate: a cardiovascular risk factor? Eur Heart J. 2006 Oct; 27(20): 2387–93. doi: 10.1093/ eurheartj/ehl259.

135. Cazzola M. et al. Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases. Drugs. 2017 May; 77(7): 721–32. doi: 10.1007/s40265-017-0731-3.

136. Nong Z. et al. Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Circulation. 1996 Oct 15; 94(8): 1941–47. PMID: 8873672.

137. Studdy P.R. et al. Angiotensin-converting enzyme and its clinical significance – a review. J Clin Pathol. 1983 Aug; 36(8): 938–47. PMID: 6308066.

138. Kakar S.S. et al. Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. Biochem. Biophys. Res. Commun. 1992. Mar; 183: 1090–96. PMID: 1567388.

139. Skwarski K.M. et al. Effects of hypoxia on renal hormonal balance in normal subjects and in patients with COPD. Respir Med. 1998 Dec; 92(12): 1331–36. PMID: 10197226.

140. Andreas S. et al. Neurohumoral activation as a link to systemic manifestation of chronic lung disease. Chest. 2005 Nov; 128(5): 3618–24. doi: 10.1378/chest.128.5.3618.

141. Marshall R.P. The pulmonary renin-angiotensin system. Curr Pharm Des. 2003; 9(9): 715–22. PMID: 12570789.

142. Chao J. et al. Monocyte chemoattractant protein-1 released from alveolar macrophages mediates the systemic inflammation of acute alveolar hypoxia. Am. J. Respir. Cell Mol. Biol. 2011 Jul; 45: 53–61. PMID: 20813992.

143. Hanif K. et al. Reinventing the ACE inhibitors: some old and new implications of ACE inhibition. Hypertens Res. 2010 Jan; 33(1): 11–21. doi: 10.1038/hr.2009.184.

144. Kaparianos A. et al. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem. 2011; 18(23): 3506–15. PMID: 21756232.

145. Wong M.H. et al. LPS-stimulated cytokine production in type I cells is modulated by the renin-angiotensin system. Am J Respir Cell Mol Biol. 2012 May; 46(5): 641–50. doi: 10.1165/rcmb.2011-0289OC.

146. Podowski M. et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J Clin Invest. 2012 Jan; 122(1): 229–40. doi: 10.1172/JCI46215.

147. Bullock G.R. et al. Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem. Cell. Biol. 2001 Feb; 115(2): 117–24.

148. Benigni A. et al. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010 Jul; 2(7): 247–57. doi: 10.1002/emmm.201000080.

149. Rahman I. et al. Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. Eur Respir J. 2006 Jul; 28(1): 219–42. doi: 10.1183/09031936.06.00053805.

150. Jankowich M.D. et al. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012 Jan; 141(1): 222–31. doi: 10.1378/chest.11-1062.

151. Specks U. et al. Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung disease. Am Rev Respir Dis. 1990 Jan; 141(1): 117–23. doi: 10.1164/ajrccm/141.1.117.

152. Königshoff M. et al. The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lungfibrosis. Am J Respir Cell Mol Biol. 2007 Dec; 37(6): 640–50. doi: 10.1165/rcmb.2006-0379TR.

153. Bradford C.N. et al. Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy. Curr Hypertens Rep. 2010 Aug; 12(4): 212–19. doi: 10.1007/ s11906-010-0122-6.

154. Man W.D. et al. Abdominal muscle and quadriceps strength in chronic obstructive pulmonary disease. Thorax. 2005 Sep; 60(9): 718–22. doi: 10.1136/thx.2005.040709.

155. Man W.D. et al. Non-volitional assessment of skeletal muscle strength in patients with chronic obstructive pulmonary disease. Thorax. 2003 Aug; 58(8): 665–69. PMID: 12885979.

156. Gosker H.R. et al. Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J. 2003 Aug; 22(2): 280–85. PMID: 12952261.

157. Gosker H.R. et al. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax. 2007 Nov; 62(11): 944–49. doi: 10.1136/ thx.2007.078980.

158. Swallow E.B. et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax. 2007 Feb; 62(2): 115–20. doi: 10.1136/thx.2006.062026.

159. Zoll J. et al. ACE inhibition prevents myocardial infarction-induced skeletal muscle mitochondrial dysfunction. J Appl Physiol (1985). 2006 Aug; 101(2): 385–91. doi: 10.1152/japplphysiol.01486.2005.

160. Guo Q. et al. Effects of estradiol, angiotensin-converting enzyme inhibitor and exercise training on exercise capacity and skeletal muscle in old female rats. Clin Exp Hypertens. 2010 Jan; 32(2): 76–83. doi: 10.3109/10641960902993046.

161. Brice E.A. et al. Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD. Chest. 1995 Mar; 107(3): 706–10. PMID: 7874941.

162. Ucar G. et al. Serum angiotensin converting enzyme activity in pulmonary diseases: correlation with lung function parameters. Life Sci. 1997; 61(11): 1075–82. PMID: 9307053.

163. Shrikrishna D. et al. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond). 2012 Oct; 123(8): 487–98. doi: 10.1042/CS20120081.

164. Агеев Ф.Т. Роль эндотелиальной дисфункции в развитии и прогрессировании сердечно-сосудистых забо- леваний. Сердечная недостаточность. 2003; 1: 22–25.

165. Манухина Е.Б. с соавт. Роль оксида азота и кислородных свободных радикалов в развитии артериальной гипертензии. Кардиология. 2002; 42(11): 73–84.

166. Мартынов А.И. с соавт. Эндотелиальная дисфункция и ангиотензинпревращающий фермент при арте- риальной гипертензии (генетические аспекты). Кардиоваскулярная терапия и профилактика. 2004; 3(5): 114–117.

167. Shimbo D. et al. Endothelial dysfunction and the risk of hypertension: the multi-ethnic study of atherosclerosis. Hypertension. 2010 May; 55(5): 1210–16. doi: 10.1161/HYPERTENSIONAHA.109.143123.

168. Luscher T.F. et al. Biology of the endothelium. Clin Cardiol. 1997 Nov; 20(11 Suppl 2): II–3–10. PMID: 9422846.

169. Shimokawa H. Endothelial dysfunction in hypertension. J Atheroscler Thromb. 1998; 4(3): 118–27. PMID: 9730143.

170. Taddei S. et al. Endothelial dysfunction in essential hypertension: clinical implications. J Hypertens. 2002 Sep; 20(9): 1671–74. PMID: 12195098.

171. Vane J.R. et al. Regulatory functions of the vascular endotnelium. N Engl J Med. 1990 Jul 5; 323(1): 27–36. doi: 10.1056/NEJM199007053230106.

172. Chandra D. et al. Airflow limitation and endothelial dysfunction. Unrelated and independent predictors of atherosclerosis. Am J Respir Crit Care Med. 2016 Jul 1; 194(1): 38–47. doi: 10.1164/rccm.201510-2093OC.

173. Anderson T.J. et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995 Nov 1; 26(5): 1235–41. PMID: 7594037.

174. MalerbaM.etal.Thepotentialroleofendothelialdysfunctionandplateletactivationinthedevelopmentofthrombotic risk in COPD patients. Expert Rev Hematol. 2017 Sep; 10(9): 821–32. doi: 10.1080/17474086.2017.1353416.

175. Ambrosino P. et al. Clinical assessment of endothelial function in patients with chronic obstructive pulmonary disease: a systematic review with meta-analysis. Intern Emerg Med. 2017 Sep; 12(6): 877–85. doi: 10.1007/ s11739-017-1690-0.

176. Vukic Dugac A. et al. Persistent endothelial dysfunction turns the frequent exacerbator COPD from respiratory disorder into a progressive pulmonary and systemic vascular disease. Med Hypotheses. 2015 Feb; 84(2): 155–58. doi: 10.1016/j.mehy.2014.11.017.

177. Кароли Н.А. с соавт. Дисфункция эндотелия сосудов у больных хроническими болезнями легких. Туберкулез и болезни легких. 2004; 4: 19–23.

178. Eickhoff P. et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Dec 15; 178(12): 1211–18. doi: 10.1164/rccm.200709- 1412OC.

179. Lyamina N.P. et al. Nitric oxide production and intensity of free radical processes in young men with high normal and hypertensive blood pressure. Med Sci Monit. 2003 Jul; 9(7): CR304–10. PMID: 12883449.

180. Lacy F. et al. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens. 1998 Mar; 16(3): 291–303. PMID: 9557922.

181. Мациевич М.В. с соавт. Комбинированная антигипертензивная терапия у пациентов с хронической обструктивной болезнью легких. Кардиоваскулярная терапия и профилактика. 2008; 7(4): 72–77.

182. Задионченко В.С. с соавт. Клинико-функциональные характеристики артериальной гипертонии у больных ХОБЛ. Сердце. 2009; 8(6): 345–350.

183. Шальнев В.И. Роль воспалительных факторов в патогенезе атеросклеротического поражения сосудов. Российский семейный врач. 2005; 9(3): 4–11.

184. Ammirati E. et al. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. Mediators Inflamm. 2015; 2015: 718329. doi: 10.1155/2015/718329.

185. Park K.H. et al. Endothelial dysfunction: clinical implications in cardiovascular disease and therapeutic approaches. J Korean Med Sci. 2015 Sep; 30(9): 1213–25. doi: 10.3346/jkms.2015.30.9.1213.

186. Nagel T. et al. Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. J Clin Invest. 1994 Aug; 94(2): 885–91. doi: 10.1172/JCI117410.

187. Van Eeden S. et al. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012 Jul 1; 186(1): 11–16. doi: 10.1164/rccm.201203-0455PP.

188. Barr R.G. et al. Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med. 2007 Dec 15; 176(12): 1200–07. doi: 10.1164/rccm.200707-980OC.

189. Sabit R. et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007 Jun 15; 175(12): 1259–65. doi: 10.1164/rccm.200701-067OC.

190. Mills N.L. et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax. 2008 Apr; 63(4):306–11. doi: 10.1136/thx.2007.083493.

191. Zieman S.J. et al. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005 May; 25(5): 932–43. doi: 10.1161/01.ATV.0000160548.78317.29.

192. Lee H.Y. et al. Aging and arterial stiffness. Circ J. 2010 Nov; 74(11): 2257–62. PMID: 20962429.

193. MacNee W. Accelerated lung aging: a novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD). Biochem Soc Trans. 2009 Aug; 37(Pt 4): 819–23. doi: 10.1042/BST0370819.

194. Suki B. et al. Mechanical failure, stress redistribution, elastase activity and binding site availability on elastin during the progression of emphysema. Pulm Pharmacol Ther. 2012 Aug; 25(4):268–75. doi: 10.1016/j. pupt.2011.04.027.

195. Кароли Н.А. с соавт. Артериальная ригидность у больных хронической обструктивной болезнью легких. Клиническая медицина. 2012; 90(9): 38–42.

196. Гельцер Б.И. с соавт. Оценка артериальной ригидности у больных хронической обструктивной болезнью легких. Пульмонология. 2008; 1: 45–50.

197. Maclay J.D. et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax. 2012 Jul; 67(7): 606–12. doi: 10.1136/thoraxjnl-2011-200949.

198. Huang J.T. et al. Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease. Eur Respir J. 2016 Oct; 48(4): 1215–18. doi: 10.1183/13993003.01125-2016.

199. Maclay J.D.et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Sep 15; 180(6): 513–20. doi: 10.1164/rccm.200903-0414OC.

200. McAllister D.A. et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007 Dec 15; 176(12): 1208–14. doi: 10.1164/ rccm.200707-1080OC.

201. Qvist L. et al. Central arterial stiffness is increased among subjects with severe and very severe COPD: report from a population-based cohort study. Eur Clin Respir J. 2015 Mar 16; 2. doi: 10.3402/ecrj.v2.27023.

202. Laurent S. et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006 Nov; 27(21): 2588–605. doi: 10.1093/eurheartj/ehl254.

203. Vivodtzev I. et al. Arterial stiffness in COPD. Chest. 2014 Apr; 145(4): 861–75. doi: 10.1378/chest.13-1809.

204. Vlachopoulos C. et al. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 Mar 30; 55(13): 1318–27. doi: 10.1016/j. jacc.2009.10.061.

205. Cosio M.G. et al. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009 Jun 4; 360(23): 2445–54. doi: 10.1056/NEJMra0804752.

206. Mannino D.M. et al. Fibrinogen, COPD and mortality in a national representative U.S. cohort. COPD. 2012 Aug; 9(4): 359–66. doi: 10.3109/15412555.2012.668249.

207. Yende S. et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax. 2006 Jan; 61(1):10–16. doi: 10.1136/ thx.2004.034181.

208. Agustí A. et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012; 7(5): e37483. doi: 10.1371/journal.pone.0037483.

209. Sin D.D. et al. Interleukin-6: a red herring or a real catch in COPD? Chest. 2008 Jan; 133(1): 4–6. doi: 10.1378/ chest.07-2085.

210. Cockayne D.A. et al. Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS One. 2012; 7(6): e38629. doi: 10.1371/journal.pone.0038629.

211. Walter R.E. et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest. 2008 Jan; 133(1): 19–25. doi: 10.1378/chest.07-0058.

212. Авдеев С.Н. с соавт. Какую информацию дает С-реактивный белок у больных ХОБЛ? Пульмонология и аллергология. 2007; 3: 11–14.

213. Verma S. et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002 Apr 23; 105(16): 1890–96. PMID: 11997273.

214. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999 Jan 14; 340(2): 115–26. doi: 10.1056/NEJM199901143400207.

215. Gan W.Q. et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004 Jul; 59(7): 574–80. PMID: 15223864.

216. Авдеев С.Н. с соавт. ХОБЛ и сердечно-сосудистые заболевания: механизмы ассоциации. Пульмонология. 2008; 1: 5–13.

217. Ridker P.M. et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003 Jan 28; 107(3): 391–97. PMID: 12551861.

218. Danesh J. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta- analyses. BMJ. 2000 Jul 22; 321(7255): 199–204. PMID: 10903648.

219. Wilson P.W. et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008 Nov; 1(2): 92–97. doi: 10.1161/CIRCOUTCOMES.108.831198.

220. Pinto-Plata V.M. et al. C-reactive protein in patients with COPD, control smokers, and non-smokers. Thorax. 2006 Jan; 61(1): 23–28. doi: 10.1136/thx.2005.042200.

221. de Torres J.P. et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest. 2008 Jun; 133(6): 1336–43. doi: 10.1378/chest.07-2433.

222. Dalekos G.N. et al. Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J. Lab. Clin. Med. 1997 Mar; 129: 300–08. PMID: 9042815.

223. Peeters A.C. et al. Pro-inflammatory cytokines in patients with essential hypertension. Eur J Clin Invest. 2001 Jan; 31(1): 31–36. PMID: 11168436.

224. Sung K.C. et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 2003 Jun; 16(6): 429–33. PMID: 12799089.

225. Sesso H.D. et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003 Dec 10; 290(22): 2945–51. doi: 10.1001/jama.290.22.2945.

226. Bautista L.E. et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005 Feb; 19(2): 149–54. doi: 10.1038/ sj.jhh.1001785.

227. Miller J. et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013 Sep; 107(9): 1376–84. doi: 10.1016/j.rmed.2013.05.001.

228. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med. 2000 Jul 27; 343(4): 269–80. doi: 10.1056/ NEJM200007273430407.

229. Fischer B.M. et al. Pathogenetic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis. 2011; 6: 413–21. doi: 10.2147/COPD.S10770.

230. Соодаева С.К. Свободно-радикальные механизмы повреждения при болезнях органов дыхания. Пульмонология. 2012; 1: 5–10.

231. Cachofeiro V. et al. Inflammation: a link between hypertension and Atherosclerosis. Current Hypertension Reviews. 2009; 5(1): 40–48. doi: 10.2174/157340209787314333.

232. Toker A. et al. Investigation of oxidative stress markers in essential hypertension. Clin Lab. 2013; 59(1–2): 107–14. PMID: 23505914.

233. Portaluppi F. et al. Oxidative stress in essential hypertension. Curr Pharm Des. 2004; 10(14): 1695–98. PMID: 15134566.

234. Redon J. et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension. 2003 May; 41(5): 1096–101. doi: 10.1161/01.HYP.0000068370.21009.38.

235. Зенков Н.К. с соавт. Окислительный стресс. Биохимические и патофизиологические аспекты. М.: Наука Интерпериодика, 2001: 343; ISBN 5-7846-0050-8.

236. Bhadoria P. et al. Correlation of systemic blood pressure in chronic obstructive pulmonary disease with serum malondiadehyde level. Am. J. Respir. Crit. Care Med. 2012 May; 185: A 1297. doi: 10.1164/ajrccm- conference.2012.185.1_MeetingAbstracts.A1297.

237. Shameem M. et al. Role of oxidative stress biomarker and its correlation with disease severity in chronic obstructive airway disease. Chest. 2011 Oct; 140(4): 585A. doi: https://doi.org/10.1378/chest.1108195.

238. Авдеев С.Н. Хроническая обструктивная болезнь легких как системное заболевание. Пульмонология. 2007; 2: 104–117.

239. Barnes P.J. et al. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009 May; 33(5): 1165–85. doi: 10.1183/09031936.00128008.

240. Хроническая обструктивная болезнь легких: монография. Под ред. А.Г. Чучалина (Серия монографий рос- сийского респираторного общества). 2-е изд., стереотип. Атмосфера. 2011: 567. ISBN 978-5-902123-27-9.

241. Young R. et al. Comorbidities in COPD. Eur Respir J. 2009 Dec; 34(6): 1497–98; author reply 1498. doi: 10.1183/09031936.00117209.

242. Задионченко В.С. с соавт. Клинико-функциональные особенности артериальной гипертонии у больных хроническими обструктивными болезнями легких. Русский медицинский журнал. 2003; 11(9): 535–539.

243. Задионченко В.С. с соавт. Артериальная гипертония у больных хроническими обструктивными болезнями легких: клинико-функциональные особенности, выбор терапии. Кардиоваскулярная терапия и профилак- тика. 2004; 3(4): 33–42.

244. Адашева Т.В. с соавт. Артериальная гипертония и ХОБЛ: патогенетические параллели и клинико-функци- ональные особенности. CаrdioСоматика. 2010; 1: 31–37.

245. Задионченко В.С. с соавт. Артериальная гипертония у больных хронической обструктивной болезнью лег- ких (20-летний опыт изучения). Медицинский совет. 2012; 10: 10–17.

246. Ли В.В. с соавт. Артериальная гипертония у больных хронической обструктивной болезнью легких – в поис- ках фенотипов. Часть I. Архив внутренней медицины. 2013; 1(9): 19–24.

247. Ли В.В. с соавт. Артериальная гипертония у больных хронической обструктивной болезнью легких – в поис- ках фенотипов. Часть II. Архив внутренней медицины. 2013; 2(10): 29–34.

248. Кароли Н.А. с соавт. Суточное мониторирование артериального давления у пациентов с хронической обструктивной болезнью легких. Саратовский научно-медицинский журнал. 2009; 5(1): 64–67.

249. Ли В.В. с соавт. Современные аспекты ремоделирования сердца у больных хронической обструктивной болезнью легких. Рациональная фармакотерапия в кардиологии. 2018; 14(3): 379–386. doi: 10.20996/1819- 6446-2018-14-3-379-386.

250. Barr R.G. et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010 Jan 21; 362(3): 217–27. doi: 10.1056/NEJMoa0808836.

251. Kubota Y. et al. COPD advances in left ventricular diastolic dysfunction. Int J Chron Obstruct Pulmon Dis. 2016 Mar 29; 11: 649–55. doi: 10.2147/COPD.S101082.

252. Boussuges A. et al. Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study. Am J Respir Crit Care Med. 2000 Aug; 162(2 Pt 1): 670–75. doi: 10.1164/ ajrccm.162.2.9908056.

253. Watz H. et al. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross- sectional study. Am J Respir Crit Care Med. 2008 Apr 1; 177(7): 743–51. doi: 10.1164/rccm.200707-1011OC.

254. Paulus W.J. et al. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013 Jul 23; 62(4): 263–71. doi: 10.1016/j.jacc.2013.02.092.

255. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010 Jun 12; 375(9731): 2073–81. doi: 10.1016/S0140- 6736(10)60674-5.

256. van der Velde M. et al. Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta- analysis of high-risk population cohorts. Kidney Int. 2011 Jun; 79(12): 1341–52. doi: 10.1038/ki.2010.536.

257. Astor B.C. et al. Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011 Jun; 79(12): 1331–40. doi: 10.1038/ki.2010.550.

258. Komurcuoğlu A. et al. Microalbuminuria in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis. 2003 Oct-Dec; 59(4): 269–72. PMID: 15148835.

259. Casanova C. et al. Microalbuminuria and hypoxia in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010 Oct 15; 182(8): 1004–10. doi: 10.1164/rccm.201003-0360OC.

260. Bulcun E. et al. Microalbuminuria in chronic obstructive pulmonary disease. COPD. 2013 Apr; 10(2): 186–92. doi: 10.3109/15412555.2012.735292.

261. Romundstad S. et al. COPD and microalbuminuria: a 12-year follow-up study. Eur Respir J. 2014 Apr; 43(4): 1042–50. doi: 10.1183/09031936.00160213.

262. Casanova C. et al. Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD. Eur Respir J. 2014 Apr; 43(4): 951–53. doi: 10.1183/09031936.00015614.

263. Gaddam S. et al. Prevalence of chronic kidney disease in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulm Med. 2016 Nov 24; 16(1): 158. doi: 10.1186/s12890-016-0315-0.

264. Chen C.Y. et al. Chronic Obstructive Pulmonary Disease is associated with risk of Chronic Kidney Disease: A Nationwide Case-Cohort Study. Sci Rep. 2016 May 11; 6: 25855. doi: 10.1038/srep25855.

265. Адашева Т.В. с соавт. Органопротективные и плейотропные эффекты амлодипина у больных артериальной гипертонией и хронической обструктивной болезнью легких. Сердце. 2010; 9(3): 165–171.

266. Задионченко В.С. с соавт. Артериальная гипертензия и хроническая обструктивная болезнь легких – про- блемы выбора терапии. Лечащий врач. 2012; 7: 77–81.

267. Адашева Т.В. с соавт. Артериальная гипертония и ХОБЛ – рациональный выбор терапии. Русский медицин- ский журнал. 2006; 14(10): 795–800.

268. Maclay J.D. et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011 Sep; 66(9): 769–74. doi: 10.1136/thx.2010.157529.

269. Alexandre B.M. et al. Profiling the erythrocyte membrane proteome isolated from patients diagnosed with chronic obstructive pulmonary disease. J Proteomics. 2012 Dec 5; 76 Spec No.: 259–69. doi: 10.1016/j. jprot.2012.04.008.

270. Задионченко В.С. с соавт. Эффективность квинаприла при артериальной гипертонии у больных ХОБЛ. Клиническая фармакология и терапия. 2003; 12(5): 23–29.

271. Мациевич М.В. с соавт. Применение эпросартана у пациентов с артериальной гипертонией в сочетании с ХОБЛ. Клиническая фармакология и терапия. 2007; 16(4): 32–35.

272. Адашева Т.В. с соавт. Антигипертензивная терапия у больных ХОБЛ: преимущества антагонистов кальция. Рациональная фармакотерапия в кардиологии. 2008; 5: 39–45.

273. Саморукова Е.И. с соавт. Коррекция розувастатином системного воспаления, оксидативного стресса и антиоксидантной защиты у больных хронической обструктивной болезнью легких. Терапия. 2017; 1: 65–73.

274. Саморукова Е.И. с соавт. Применение розувастатина у больных хронической обструктивной болезнью легких. Международный журнал сердца и сосудистых заболеваний. 2018; 6(17): 36–44.

275. Dickinson H.O. et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomizedcontrolled trials. J Hypertens. 2006 Feb; 24(2): 215–33. doi: 10.1097/01.hjh.0000199800.72563.26.

276. Groppelli A. et al. Persistent blood pressure increase induced by heavy smoking. J Hypertens. 1992 May; 10(5): 495–99. PMID: 1317911.

277. Mann S.J. et al. Elevation of ambulatory systolic blood pressure in hypertensive smokers. A case-control study. JAMA. 1991 May 1; 265(17): 2226–28. PMID: 2013955.

278. Stead L.F. et al. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016 Mar 24; 3: CD008286. doi: 10.1002/14651858.CD008286.pub3.

279. Spruit M.A. et al. ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/ European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013 Oct 15; 188(8): e13–64. doi: 10.1164/rccm.201309-1634ST.

280. Berry M.J. et al. Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Crit Care Med 1999; 160: 1248–53. doi: 10.1164/ajrccm.160.4.9901014.

281. Малявин А.Г. с соавт. Разработка интерактивной системы экспертной поддержки врачебных решений по рациональному назначению лекарственных препаратов при коморбидности. Ремедиум. 2016; 11: 38–41. doi: 10.21518/1561-5936-2016-11-52-55.

282. Адашева Т.В. с соавт. Экспертная поддержка врачебных решений рационального назначения лекарствен- ных препаратов в условиях полиморбидности. Терапия. 2016; 6: 24–26.